SCHEMBL2247429

SCHEMBL2247429

CC(C)(Cc1ccccc1)N(C(=O)c1ccc2c(c1)Cc1ccccc1-2)[C@@H](CCC(=O)O)C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 1/20 0.43
HTR2C P28335 2/20 0.41
HTR2B P41595 2/20 0.41
DRD2 P14416 1/20 0.41
ADRA1D P25100 1/20 0.41
HTR2A P28223 1/20 0.41
HTR7 P34969 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41
MCHR1 Q99705 1/20 0.39
MMP12 P39900 1/20 0.38
MMP13 P45452 1/20 0.38
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
SLC1A3 P43003 2/20 0.35
SLC1A2 P43004 2/20 0.35
SLC1A1 P43005 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2248586 0.94 GCGR (0.40) SRD5A2HTR2CHTR2BDRD2ADRA1D
SCHEMBL2245097 0.81 KMT2A (0.37) MMP12ALDH1A1LMNAL3MBTL1CYP3A4
SCHEMBL2246681 0.79 TSHR (0.36) MMP12ALDH1A1LMNAGAAMAPT
SCHEMBL4369267 0.79 SRD5A2 (0.46) SRD5A2HTR2CHTR2BDRD2ADRA1D
SCHEMBL2249342 0.78 MMP12 (0.43) MMP12MMP13ALDH1A1MAPTMMP2
SCHEMBL2251275 0.78 MMP12 (0.40) MMP12MMP13ALDH1A1LMNACYP1A2
SCHEMBL2247535 0.77 MMP12 (0.40) MMP12MMP13ALDH1A1MAPTMMP2
SCHEMBL2249506 0.77 F10 (0.40) KDM4EALDH1A1CYP1A2MAPTPOLB
SCHEMBL2248530 0.77 PDE4A (0.45) MCHR1MAPTCYP3A4
SCHEMBL2248047 0.76 GABRA1 (0.45) ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US claimed
US-7998965-B2 Glutamate aggrecanase inhibitors WYETH LLC (US) 2011-08-16 US disclosed
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS WYETH (US) 2010-01-14 US disclosed
US-7553873-B2 Glutamate aggrecanase inhibitors WYETH (US) 2009-06-30 US disclosed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS ADAMTS5, ADAMTS1, ADAMTS7 SRD5A2 3124/4885HTR2C 2900/4885HTR2B 2096/4885
US-20070043066-A1 Glutamate aggrecanase inhibitors ADAMTS5, ADAMTS1, ADAMTS7 SRD5A2 3124/4885HTR2C 2900/4885HTR2B 2096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.